CLEVELAND – February 19, 2014
BioMotiv has established Kodosil Bio to develop the IL-22 antibody obtained from an exclusive worldwide license from BioAtla, a global biotechnology company focused on the development of conditionally active biologics. The antibody is directed at a novel validated target in the Th22 cell/IL-22 pathway that plays a key role in gastrointestinal autoimmune and inflammatory processes.

Click here to read more